Advertisement
Screener

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Corbus Pharmaceuticals Holdings, Inc. Research and Development Expense

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Research and Development Expense of $31.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06

  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $31.18M, a 105.27% increase year-over-year.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $19.82M, a 26.70% increase year-over-year.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2025-12-31 was $18.41M, a 109.47% increase year-over-year.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for the quarter ending 2025-09-30 was $20.86M, a 93.01% increase year-over-year.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2025 was $70.09M, a 117.54% increase from fiscal 2024.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2024 was $32.22M, a 3.38% increase from fiscal 2023.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2023 was $31.17M, a 93.15% increase from fiscal 2022.
  • Corbus Pharmaceuticals Holdings, Inc. research and development expense for fiscal 2022 was $16.14M, a 55.72% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$31.18M
10-Q · filed 2026-08-06
$50.99M
10-Q · filed 2026-08-06
$69.40M
derived: sum of 3 quarters · filed 2026-08-06
$90.26M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$19.82M
10-Q · filed 2026-05-12
$38.23M
derived: sum of 2 quarters · filed 2026-05-12
$59.09M
derived: sum of 3 quarters · filed 2026-05-12
$74.27M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$18.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$39.27M
derived: sum of 2 quarters · filed 2026-03-09
$54.45M
derived: sum of 3 quarters · filed 2026-08-06
$70.09M
10-K · filed 2026-03-09
2025-09-30$20.86M
10-Q · filed 2025-11-12
$36.05M
derived: sum of 2 quarters · filed 2026-08-06
$51.69M
10-Q · filed 2025-11-12
$60.48M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$15.19M
10-Q · filed 2026-08-06
$30.83M
10-Q · filed 2026-08-06
$39.62M
derived: sum of 3 quarters · filed 2026-08-06
$50.42M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$15.64M
10-Q · filed 2026-05-12
$24.43M
derived: sum of 2 quarters · filed 2026-05-12
$35.24M
derived: sum of 3 quarters · filed 2026-05-12
$42.10M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$8.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$19.59M
derived: sum of 2 quarters · filed 2026-03-09
$26.46M
derived: sum of 3 quarters · filed 2026-03-09
$32.22M
10-K · filed 2026-03-09
2024-09-30$10.81M
10-Q · filed 2025-11-12
$17.67M
derived: sum of 2 quarters · filed 2025-11-12
$23.43M
10-Q · filed 2025-11-12
$30.41M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$6.87M
10-Q · filed 2025-08-05
$12.63M
10-Q · filed 2025-08-05
$19.61M
derived: sum of 3 quarters · filed 2025-08-05
$26.16M
derived: sum of 4 quarters · filed 2025-08-05
2024-03-31$5.76M
10-Q · filed 2025-05-06
$5.76M
10-Q · filed 2024-05-07
$12.74M
derived: sum of 2 quarters · filed 2025-05-06
$19.29M
derived: sum of 3 quarters · filed 2025-05-06
$23.54M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$6.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$13.53M
derived: sum of 2 quarters · filed 2025-03-11
$17.78M
derived: sum of 3 quarters · filed 2025-03-11
$31.17M
10-K · filed 2025-03-11
$31.17M
10-K · filed 2024-03-12
2023-09-30$6.55M
10-Q · filed 2024-11-07
$6.55M
10-Q · filed 2023-11-07
$10.80M
derived: sum of 2 quarters · filed 2024-11-07
$24.19M
10-Q · filed 2024-11-07
$24.19M
10-Q · filed 2023-11-07
$30.43M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$4.25M
10-Q · filed 2024-08-06
$4.25M
10-Q · filed 2023-08-08
$17.64M
10-Q · filed 2024-08-06
$17.64M
10-Q · filed 2023-08-08
$23.88M
derived: sum of 3 quarters · filed 2024-08-06
$27.99M
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31$13.39M
10-Q · filed 2024-05-07
$19.63M
derived: sum of 2 quarters · filed 2024-05-07
$23.74M
derived: sum of 3 quarters · filed 2024-05-07
$26.24M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31$6.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
$10.35M
derived: sum of 2 quarters · filed 2024-03-12
$12.85M
derived: sum of 3 quarters · filed 2024-03-12
$16.14M
10-K · filed 2024-03-12
2022-09-30$4.11M
10-Q · filed 2023-11-07
$6.61M
derived: sum of 2 quarters · filed 2023-11-07
$9.89M
10-Q · filed 2023-11-07
$10.27M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$2.50M
10-Q · filed 2023-08-08
$5.79M
10-Q · filed 2023-08-08
$6.17M
derived: sum of 3 quarters · filed 2023-08-08
$14.86M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31$3.29M
10-Q · filed 2023-05-09
$3.67M
derived: sum of 2 quarters · filed 2023-05-09
$12.36M
derived: sum of 3 quarters · filed 2023-05-09
$23.63M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$380.00K
10-Q · filed 2022-11-08
$9.08M
derived: sum of 2 quarters · filed 2022-11-08
$20.34M
derived: sum of 3 quarters · filed 2022-11-08
$36.45M
10-K · filed 2023-03-07
2021-09-30$8.70M
10-Q · filed 2022-11-08
$19.96M
derived: sum of 2 quarters · filed 2022-11-08
$30.68M
10-Q · filed 2022-11-08
$46.79M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$11.27M
10-Q · filed 2022-08-09
$21.99M
10-Q · filed 2022-08-09
$38.10M
derived: sum of 3 quarters · filed 2022-08-09
$65.62M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$10.72M
10-Q · filed 2022-05-10
$26.83M
derived: sum of 2 quarters · filed 2022-05-10
$54.35M
derived: sum of 3 quarters · filed 2022-05-10
$85.04M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31$16.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$43.63M
derived: sum of 2 quarters · filed 2022-03-08
$74.32M
derived: sum of 3 quarters · filed 2022-03-08
$98.27M
10-K · filed 2022-03-08
2020-09-30$27.52M
10-Q · filed 2021-11-12
$58.21M
derived: sum of 2 quarters · filed 2021-11-12
$82.16M
10-Q · filed 2021-11-12
$105.64M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$30.69M
10-Q · filed 2021-08-12
$54.63M
10-Q · filed 2021-08-12
$78.12M
derived: sum of 3 quarters · filed 2021-08-12
$100.27M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$23.95M
10-Q · filed 2021-05-13
$47.44M
derived: sum of 2 quarters · filed 2021-05-13
$69.59M
derived: sum of 3 quarters · filed 2021-05-13
$91.77M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$23.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15
$45.64M
derived: sum of 2 quarters · filed 2021-03-15
$67.82M
derived: sum of 3 quarters · filed 2021-03-15
$89.60M
10-K · filed 2021-03-15
2019-09-30$22.15M
10-Q · filed 2020-11-09
$44.33M
derived: sum of 2 quarters · filed 2020-11-09
$66.12M
10-Q · filed 2020-11-09
$81.90M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30$22.18M
10-Q/A · filed 2020-08-31
$43.97M
10-Q/A · filed 2020-08-31
$59.75M
derived: sum of 3 quarters · filed 2020-08-31
$72.55M
derived: sum of 4 quarters · filed 2020-08-31
2019-03-31$21.78M
10-Q · filed 2020-05-11
$37.56M
derived: sum of 2 quarters · filed 2020-05-11
$50.37M
derived: sum of 3 quarters · filed 2020-05-11
$60.63M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31$15.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$28.59M
derived: sum of 2 quarters · filed 2020-03-16
$38.85M
derived: sum of 3 quarters · filed 2020-03-16
$48.61M
10-K · filed 2020-03-16
2018-09-30$12.81M
10-Q · filed 2019-11-07
$23.07M
derived: sum of 2 quarters · filed 2019-11-07
$32.83M
10-Q · filed 2019-11-07
$41.12M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30$10.26M
10-Q · filed 2019-08-08
$20.03M
10-Q · filed 2019-08-08
$28.31M
derived: sum of 3 quarters · filed 2019-08-08
$33.93M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31$9.77M
10-Q · filed 2019-05-09
$18.05M
derived: sum of 2 quarters · filed 2019-05-09
$23.67M
derived: sum of 3 quarters · filed 2019-05-09
$29.44M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$8.29M
10-K · filed 2018-03-12
$13.91M
derived: sum of 2 quarters · filed 2018-11-08
$19.67M
derived: sum of 3 quarters · filed 2018-11-08
$26.04M
10-K · filed 2019-03-12
2017-09-30$5.62M
10-Q · filed 2018-11-08
$11.39M
derived: sum of 2 quarters · filed 2018-11-08
$17.75M
10-Q · filed 2018-11-08
$23.13M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30$5.76M
10-Q · filed 2018-08-08
$12.13M
10-Q · filed 2018-08-08
$17.51M
derived: sum of 3 quarters · filed 2018-08-08
$21.83M
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31$6.37M
10-K · filed 2018-03-12
$11.75M
derived: sum of 2 quarters · filed 2018-05-10
$16.06M
derived: sum of 3 quarters · filed 2018-05-10
$19.63M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$5.38M
10-K · filed 2018-03-12
$9.70M
derived: sum of 2 quarters · filed 2018-03-12
$13.26M
derived: sum of 3 quarters · filed 2018-03-12
$15.44M
10-K · filed 2018-03-12
2016-09-30$4.32M
10-K · filed 2018-03-12
$7.88M
derived: sum of 2 quarters · filed 2018-03-12
$10.06M
10-Q · filed 2017-11-08
$11.88M
derived: sum of 4 quarters · filed 2018-03-12
2016-06-30$3.57M
10-K · filed 2018-03-12
$5.74M
10-Q · filed 2017-08-09
$7.56M
derived: sum of 3 quarters · filed 2018-03-12
$9.20M
derived: sum of 4 quarters · filed 2018-03-12
2016-03-31$2.17M
10-K · filed 2018-03-12
$4.00M
derived: sum of 2 quarters · filed 2018-03-12
$5.63M
derived: sum of 3 quarters · filed 2018-03-12
$7.34M
derived: sum of 4 quarters · filed 2018-03-12
2015-12-31$1.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$3.46M
derived: sum of 2 quarters · filed 2018-03-12
$5.17M
derived: sum of 3 quarters · filed 2018-03-12
$5.89M
10-K · filed 2018-03-12
2015-09-30$1.63M
10-Q · filed 2016-11-10
$3.34M
derived: sum of 2 quarters · filed 2016-11-10
$4.07M
10-Q · filed 2016-11-10
$4.64M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30$1.71M
10-Q · filed 2016-08-12
$2.43M
10-Q · filed 2016-08-12
$3.00M
derived: sum of 3 quarters · filed 2016-08-12
$3.45M
derived: sum of 4 quarters · filed 2016-08-12
2015-03-31$723.43K
10-Q · filed 2016-05-13
$1.30M
derived: sum of 2 quarters · filed 2016-05-13
$1.75M
derived: sum of 3 quarters · filed 2016-05-13
$1.92M
derived: sum of 4 quarters · filed 2016-05-13
2014-12-31$571.58K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28
$1.02M
derived: sum of 2 quarters · filed 2016-03-28
$1.19M
derived: sum of 3 quarters · filed 2016-03-28
$1.26M
10-K · filed 2016-03-28
2014-09-30$452.60K
10-Q · filed 2015-11-10
$622.04K
derived: sum of 2 quarters · filed 2015-11-10
$683.96K
10-Q · filed 2015-11-10
$668.71K
derived: sum of 4 quarters · filed 2015-11-10
2014-06-30$169.44K
10-Q · filed 2015-08-13
$231.36K
10-Q · filed 2015-08-13
$216.11K
derived: sum of 3 quarters · filed 2015-08-13
$245.08K
derived: sum of 4 quarters · filed 2015-08-13
2014-03-31$61.92K
10-Q · filed 2015-05-13
$46.66K
derived: sum of 2 quarters · filed 2015-05-13
$75.64K
derived: sum of 3 quarters · filed 2015-05-13
2013-12-31-$15.25K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-10
$13.72K
derived: sum of 2 quarters · filed 2015-02-10
$210.67K
10-K · filed 2015-02-10
2013-09-30$28.97K
10-Q · filed 2014-11-13
$225.92K
10-Q · filed 2014-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Annexon, Inc. (ANNX)United States$0.147B-4.22
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88